title: [Obesity and diseases of digestive organs].
abstract: Obesity is non-infectious pandemic. Its association with cardiovascular pathology is especially widely discussed, but an overweight patient is actually polymorbid. An increase of body mass provides a pathogenetic basis for many diseases including those of digestive system This review deals with pathogenesis, clinical features, and treatment of gastroesophageal reflux disease, cholelithiasis and non-alcoholic fatty liver disease in obese patients. This pathology and its aggravation result from such pathophysiological processes as a rise in intra-abdominal pressure, excess adipokine, cholesterol and free fatty acid synthesis, activation of lipid peroxidation. Gastroesophageal reflux disease in obese patients has an atypical clinical course characterized by discrepancy between clinical, endoscopic and morphological features in oesophagus and frequent formation of Barrett's oesophagus. Cholelethiasis in obesity is fraught with further progress of the disease after prescription of low-fat diet. The risk of calculi formation can be reduced by prescription of ursodeoxycholic acid that produces both litholytic and hypolipidemic effects. Treatment of non-alcoholic fatty liver disease requires combined therapy with statins, insulin sensitizers, hepatoprotectors and adequate physical activity. Sustained remission of diseases of digestive organs is impossible without correction of body mass and their pharmacotherapy requires increasing doses of medicines and duration of their administration.
authors.forename: E V
authors.initials: EV
authors.lastname: Luzina
authors.forename: E A
authors.initials: EA
authors.lastname: Tomina
authors.forename: A A
authors.initials: AA
authors.lastname: Zhilina
mesh_terms: D015992:Body Mass Index; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D002769:Cholelithiasis / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D004035:Diet Therapy / Q000379:methods; D016099:Endoscopy, Gastrointestinal; D005234:Fatty Liver / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D015438:Health Behavior; D006801:Humans; D008019:Life Style; D065626:Non-alcoholic Fatty Liver Disease; D009765:Obesity / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology; D012307:Risk Factors; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid